id int64 | sector string | outlet_id string | outlet_type string | region_type string | malaria_endemicity string | country_regulatory_maturity string | product_name string | drug_class string | dosage_form string | indication string | reference_price_usd float64 | quality_assured int64 | registered_product int64 | WHO_prequalified int64 | oral_monotherapy int64 | year int64 | quarter int64 | manufacturer_origin string | quality_test_result string | sf_classification string | failure_mode string | artemisinin_content_pct float64 | partner_drug_content_pct float64 | treatment_failure_risk int64 | estimated_malaria_deaths int64 | AMR_resistance_contribution string | price_paid_usd float64 | patient_age_group string | patient_aware_SF_risk int64 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | private_licensed | MAL_0018 | private_pharmacy | rural | mesoendemic | ML1 | artemether_lumefantrine_20_120 | ACT | tablet | first_line | 0.04 | 0 | 0 | 0 | 0 | 2,023 | 4 | India | pass | compliant | not_applicable | 99.2 | 103.6 | 0 | 0 | none | 0.1 | 15_49 | 1 |
2 | private_licensed | MAL_0171 | drug_shop | rural | hyperendemic | ML4 | artesunate_amodiaquine | ACT | tablet | first_line | 0.05 | 0 | 0 | 1 | 0 | 2,020 | 4 | India | pass | compliant | not_applicable | 104.4 | 96 | 0 | 0 | none | 0.13 | 5_14 | 0 |
3 | private_licensed | MAL_0093 | private_pharmacy | urban | mesoendemic | ML2 | dihydroartemisinin_piperaquine | ACT | tablet | first_line | 0.06 | 0 | 0 | 0 | 0 | 2,024 | 1 | India | fail | substandard | insufficient_artemisinin | 28 | 81 | 0 | 0 | high | 0.14 | 15_49 | 0 |
4 | private_licensed | MAL_0101 | health_centre | urban | mesoendemic | ML2 | artesunate_SP | ACT | tablet | IPTp | 0.04 | 0 | 0 | 0 | 0 | 2,023 | 3 | India | fail | substandard | insufficient_artemisinin | 41.6 | 60.9 | 1 | 0 | low | 0.12 | 15_49 | 0 |
5 | private_licensed | MAL_0101 | drug_shop | peri_urban | mesoendemic | ML1 | artesunate_injection_60mg | injectable | injection | severe_malaria | 0.8 | 1 | 1 | 0 | 0 | 2,021 | 4 | China | pass | compliant | not_applicable | 100.1 | 101.3 | 0 | 0 | none | 2.23 | 15_49 | 0 |
6 | private_licensed | MAL_0191 | health_centre | rural | hypoendemic | ML2 | artesunate_rectal_100mg | rectal | suppository | pre_referral | 0.5 | 1 | 0 | 0 | 0 | 2,022 | 1 | India | fail | substandard | insufficient_partner_drug | 70.7 | 86.5 | 0 | 0 | low | 1.14 | 15_49 | 0 |
7 | private_licensed | MAL_0132 | drug_shop | peri_urban | hyperendemic | ML1 | quinine_injection_300mg | injectable | injection | severe_malaria | 0.3 | 0 | 1 | 0 | 0 | 2,021 | 2 | India | pass | compliant | not_applicable | 97.4 | 93.4 | 0 | 0 | none | 0.69 | 15_49 | 1 |
8 | private_licensed | MAL_0031 | private_pharmacy | rural | holoendemic | ML2 | quinine_tablets_300mg | oral | tablet | second_line | 0.05 | 0 | 0 | 0 | 0 | 2,022 | 4 | India | pass | compliant | not_applicable | 97.5 | 97.3 | 0 | 0 | low | 0.15 | under_5 | 0 |
9 | private_licensed | MAL_0063 | drug_shop | urban | mesoendemic | ML3 | SP_sulfadoxine_pyrimethamine | SP | tablet | IPTp | 0.03 | 0 | 1 | 0 | 0 | 2,020 | 1 | China | pass | compliant | not_applicable | 96.9 | 102.2 | 0 | 0 | none | 0.1 | under_5 | 0 |
10 | private_licensed | MAL_0181 | itinerant_vendor | urban | holoendemic | ML2 | chloroquine_250mg | aminoquinoline | tablet | P_vivax | 0.01 | 0 | 0 | 0 | 0 | 2,024 | 2 | China | fail | substandard | degradation_products | 99.1 | 86.4 | 0 | 0 | low | 0.02 | under_5 | 0 |
11 | private_licensed | MAL_0014 | private_pharmacy | urban | hyperendemic | ML3 | primaquine_15mg | aminoquinoline | tablet | radical_cure | 0.08 | 1 | 1 | 0 | 0 | 2,023 | 4 | India | fail | falsified | no_artemisinin_detected | 0 | 89.7 | 1 | 0 | high | 0.19 | under_5 | 0 |
12 | private_licensed | MAL_0005 | drug_shop | urban | holoendemic | ML4 | oral_artemisinin_monotherapy | monotherapy_BANNED | tablet | banned_product | 0.02 | 1 | 1 | 0 | 1 | 2,023 | 3 | unknown | fail | substandard | insufficient_artemisinin | 51.1 | 82.6 | 1 | 0 | moderate | 0.09 | 15_49 | 0 |
13 | private_licensed | MAL_0147 | private_pharmacy | rural | holoendemic | ML1 | artemether_lumefantrine_20_120 | ACT | tablet | first_line | 0.04 | 0 | 0 | 0 | 0 | 2,023 | 4 | unknown | fail | substandard | insufficient_partner_drug | 99.2 | 78.6 | 0 | 0 | moderate | 0.16 | under_5 | 0 |
14 | private_licensed | MAL_0168 | health_centre | urban | hyperendemic | ML1 | artesunate_amodiaquine | ACT | tablet | first_line | 0.05 | 0 | 1 | 1 | 0 | 2,021 | 4 | India | pass | compliant | not_applicable | 95.6 | 96.8 | 0 | 0 | none | 0.16 | under_5 | 0 |
15 | private_licensed | MAL_0103 | private_pharmacy | peri_urban | hyperendemic | ML3 | dihydroartemisinin_piperaquine | ACT | tablet | first_line | 0.06 | 0 | 1 | 1 | 0 | 2,021 | 3 | China | pass | compliant | not_applicable | 97.1 | 92.4 | 0 | 0 | low | 0.19 | 50_plus | 0 |
16 | private_licensed | MAL_0167 | itinerant_vendor | rural | mesoendemic | ML3 | artesunate_SP | ACT | tablet | IPTp | 0.04 | 0 | 0 | 1 | 0 | 2,023 | 4 | unknown | pass | compliant | not_applicable | 98.4 | 98.9 | 0 | 0 | none | 0.11 | 5_14 | 0 |
17 | private_licensed | MAL_0121 | private_pharmacy | peri_urban | hyperendemic | ML2 | artesunate_injection_60mg | injectable | injection | severe_malaria | 0.8 | 0 | 1 | 0 | 0 | 2,023 | 1 | India | pass | compliant | not_applicable | 103.4 | 100.2 | 0 | 0 | low | 2.28 | 15_49 | 0 |
18 | private_licensed | MAL_0036 | private_pharmacy | rural | mesoendemic | ML1 | artesunate_rectal_100mg | rectal | suppository | pre_referral | 0.5 | 0 | 1 | 0 | 0 | 2,024 | 3 | India | pass | compliant | not_applicable | 97.7 | 105.6 | 0 | 0 | low | 1.33 | 50_plus | 0 |
19 | private_licensed | MAL_0144 | health_centre | rural | holoendemic | ML2 | quinine_injection_300mg | injectable | injection | severe_malaria | 0.3 | 0 | 1 | 0 | 0 | 2,024 | 3 | China | pass | compliant | not_applicable | 97.5 | 101 | 0 | 0 | none | 1.12 | 15_49 | 0 |
20 | private_licensed | MAL_0184 | drug_shop | peri_urban | mesoendemic | ML3 | quinine_tablets_300mg | oral | tablet | second_line | 0.05 | 1 | 1 | 0 | 0 | 2,021 | 4 | unknown | pass | compliant | not_applicable | 98.7 | 105.4 | 0 | 0 | none | 0.13 | 15_49 | 0 |
21 | private_licensed | MAL_0028 | itinerant_vendor | rural | hypoendemic | ML1 | SP_sulfadoxine_pyrimethamine | SP | tablet | IPTp | 0.03 | 0 | 0 | 1 | 0 | 2,023 | 2 | India | pass | compliant | not_applicable | 95 | 91.7 | 0 | 0 | none | 0.08 | under_5 | 0 |
22 | private_licensed | MAL_0147 | health_centre | rural | mesoendemic | ML1 | chloroquine_250mg | aminoquinoline | tablet | P_vivax | 0.01 | 0 | 1 | 0 | 0 | 2,023 | 4 | India | pass | compliant | not_applicable | 100.3 | 94.5 | 0 | 0 | none | 0.03 | under_5 | 0 |
23 | private_licensed | MAL_0058 | hospital_pharmacy | urban | holoendemic | ML2 | primaquine_15mg | aminoquinoline | tablet | radical_cure | 0.08 | 0 | 1 | 0 | 0 | 2,024 | 3 | unknown | pass | compliant | not_applicable | 101.7 | 104.6 | 0 | 0 | none | 0.21 | under_5 | 0 |
24 | private_licensed | MAL_0108 | drug_shop | rural | holoendemic | ML3 | oral_artemisinin_monotherapy | monotherapy_BANNED | tablet | banned_product | 0.02 | 1 | 1 | 0 | 1 | 2,024 | 3 | China | fail | substandard | insufficient_artemisinin | 72.5 | 52.5 | 1 | 0 | low | 0.05 | 5_14 | 0 |
25 | private_licensed | MAL_0051 | drug_shop | urban | hypoendemic | ML2 | artemether_lumefantrine_20_120 | ACT | tablet | first_line | 0.04 | 0 | 0 | 0 | 0 | 2,021 | 3 | China | fail | substandard | insufficient_artemisinin | 23.7 | 82.4 | 1 | 0 | moderate | 0.12 | 5_14 | 0 |
26 | private_licensed | MAL_0168 | drug_shop | peri_urban | holoendemic | ML2 | artesunate_amodiaquine | ACT | tablet | first_line | 0.05 | 0 | 1 | 0 | 0 | 2,024 | 1 | China | pass | compliant | not_applicable | 100.5 | 96.3 | 0 | 0 | none | 0.12 | 15_49 | 0 |
27 | private_licensed | MAL_0192 | drug_shop | rural | hypoendemic | ML2 | dihydroartemisinin_piperaquine | ACT | tablet | first_line | 0.06 | 0 | 0 | 0 | 0 | 2,023 | 3 | India | fail | substandard | insufficient_artemisinin | 33.2 | 86.8 | 1 | 0 | high | 0.17 | 15_49 | 0 |
28 | private_licensed | MAL_0083 | private_pharmacy | rural | holoendemic | ML2 | artesunate_SP | ACT | tablet | IPTp | 0.04 | 0 | 0 | 0 | 0 | 2,023 | 2 | local_SSA | fail | substandard | insufficient_artemisinin | 28.6 | 85.2 | 1 | 0 | high | 0.15 | 15_49 | 0 |
29 | private_licensed | MAL_0160 | health_centre | peri_urban | hyperendemic | ML1 | artesunate_injection_60mg | injectable | injection | severe_malaria | 0.8 | 0 | 1 | 0 | 0 | 2,021 | 4 | unknown | fail | falsified | no_artemisinin_detected | 0 | 71.9 | 0 | 0 | moderate | 2.09 | under_5 | 0 |
30 | private_licensed | MAL_0170 | drug_shop | rural | mesoendemic | ML1 | artesunate_rectal_100mg | rectal | suppository | pre_referral | 0.5 | 1 | 1 | 0 | 0 | 2,023 | 3 | local_SSA | pass | compliant | not_applicable | 98.8 | 96.5 | 0 | 0 | none | 1.24 | under_5 | 0 |
31 | private_licensed | MAL_0169 | health_centre | peri_urban | hypoendemic | ML2 | quinine_injection_300mg | injectable | injection | severe_malaria | 0.3 | 1 | 1 | 1 | 1 | 2,024 | 3 | India | pass | compliant | not_applicable | 95.4 | 97.7 | 0 | 0 | none | 0.77 | 15_49 | 0 |
32 | private_licensed | MAL_0160 | private_pharmacy | rural | hypoendemic | ML3 | quinine_tablets_300mg | oral | tablet | second_line | 0.05 | 0 | 0 | 0 | 0 | 2,024 | 3 | India | pass | compliant | not_applicable | 99.6 | 106.1 | 0 | 0 | high | 0.16 | 15_49 | 0 |
33 | private_licensed | MAL_0127 | health_centre | urban | mesoendemic | ML2 | SP_sulfadoxine_pyrimethamine | SP | tablet | IPTp | 0.03 | 0 | 1 | 0 | 0 | 2,024 | 2 | India | pass | compliant | not_applicable | 97.4 | 100.7 | 0 | 0 | low | 0.1 | 5_14 | 1 |
34 | private_licensed | MAL_0074 | drug_shop | rural | mesoendemic | ML3 | chloroquine_250mg | aminoquinoline | tablet | P_vivax | 0.01 | 0 | 0 | 1 | 0 | 2,023 | 1 | unknown | fail | substandard | degradation_products | 92.7 | 72 | 0 | 0 | high | 0.02 | 50_plus | 0 |
35 | private_licensed | MAL_0156 | private_pharmacy | peri_urban | hyperendemic | ML1 | primaquine_15mg | aminoquinoline | tablet | radical_cure | 0.08 | 0 | 1 | 1 | 0 | 2,024 | 4 | Europe | pass | compliant | not_applicable | 99.4 | 96.3 | 0 | 0 | none | 0.26 | 50_plus | 0 |
36 | private_licensed | MAL_0147 | private_pharmacy | rural | hyperendemic | ML1 | oral_artemisinin_monotherapy | monotherapy_BANNED | tablet | banned_product | 0.02 | 1 | 1 | 0 | 1 | 2,020 | 3 | China | pass | compliant | not_applicable | 102 | 96.4 | 0 | 0 | high | 0.06 | 5_14 | 0 |
37 | private_licensed | MAL_0069 | private_pharmacy | peri_urban | hypoendemic | ML2 | artemether_lumefantrine_20_120 | ACT | tablet | first_line | 0.04 | 0 | 1 | 0 | 0 | 2,021 | 4 | India | fail | substandard | insufficient_artemisinin | 51.5 | 85.8 | 0 | 0 | moderate | 0.13 | 50_plus | 0 |
38 | private_licensed | MAL_0051 | itinerant_vendor | rural | holoendemic | ML2 | artesunate_amodiaquine | ACT | tablet | first_line | 0.05 | 1 | 0 | 0 | 0 | 2,022 | 4 | India | pass | compliant | not_applicable | 96.9 | 94.1 | 0 | 0 | none | 0.13 | 5_14 | 0 |
39 | private_licensed | MAL_0158 | health_centre | urban | hyperendemic | ML1 | dihydroartemisinin_piperaquine | ACT | tablet | first_line | 0.06 | 0 | 1 | 0 | 0 | 2,022 | 2 | India | fail | substandard | insufficient_artemisinin | 48 | 61.8 | 1 | 0 | high | 0.15 | under_5 | 0 |
40 | private_licensed | MAL_0119 | private_pharmacy | rural | holoendemic | ML2 | artesunate_SP | ACT | tablet | IPTp | 0.04 | 0 | 1 | 0 | 0 | 2,021 | 1 | India | fail | substandard | insufficient_artemisinin | 27.2 | 92.1 | 1 | 0 | low | 0.14 | 15_49 | 0 |
41 | private_licensed | MAL_0099 | market_stall | rural | holoendemic | ML3 | artesunate_injection_60mg | injectable | injection | severe_malaria | 0.8 | 0 | 1 | 0 | 0 | 2,023 | 1 | unknown | fail | substandard | insufficient_partner_drug | 94.4 | 86.6 | 1 | 0 | moderate | 2.65 | under_5 | 0 |
42 | private_licensed | MAL_0077 | private_pharmacy | rural | mesoendemic | ML3 | artesunate_rectal_100mg | rectal | suppository | pre_referral | 0.5 | 1 | 0 | 0 | 0 | 2,021 | 1 | local_SSA | pass | compliant | not_applicable | 99.2 | 91.5 | 0 | 0 | none | 1.48 | 50_plus | 0 |
43 | private_licensed | MAL_0078 | market_stall | rural | hyperendemic | ML2 | quinine_injection_300mg | injectable | injection | severe_malaria | 0.3 | 1 | 1 | 0 | 0 | 2,023 | 1 | Europe | fail | substandard | insufficient_artemisinin | 71.8 | 80.6 | 0 | 0 | moderate | 0.95 | 15_49 | 0 |
44 | private_licensed | MAL_0152 | market_stall | rural | hyperendemic | ML2 | quinine_tablets_300mg | oral | tablet | second_line | 0.05 | 1 | 0 | 0 | 0 | 2,020 | 3 | unknown | pass | compliant | not_applicable | 99.6 | 99.4 | 0 | 0 | high | 0.14 | under_5 | 0 |
45 | private_licensed | MAL_0196 | private_pharmacy | peri_urban | mesoendemic | ML3 | SP_sulfadoxine_pyrimethamine | SP | tablet | IPTp | 0.03 | 1 | 1 | 0 | 0 | 2,024 | 4 | China | pass | compliant | not_applicable | 98.1 | 94.2 | 0 | 0 | low | 0.09 | under_5 | 0 |
46 | private_licensed | MAL_0091 | itinerant_vendor | peri_urban | mesoendemic | ML3 | chloroquine_250mg | aminoquinoline | tablet | P_vivax | 0.01 | 1 | 1 | 0 | 0 | 2,022 | 1 | China | pass | compliant | not_applicable | 97.8 | 102.5 | 0 | 0 | none | 0.03 | under_5 | 0 |
47 | private_licensed | MAL_0062 | private_pharmacy | rural | holoendemic | ML1 | primaquine_15mg | aminoquinoline | tablet | radical_cure | 0.08 | 0 | 0 | 0 | 0 | 2,021 | 3 | China | fail | falsified | no_artemisinin_detected | 0 | 64.9 | 0 | 0 | high | 0.16 | under_5 | 0 |
48 | private_licensed | MAL_0027 | market_stall | rural | hypoendemic | ML4 | oral_artemisinin_monotherapy | monotherapy_BANNED | tablet | banned_product | 0.02 | 0 | 0 | 1 | 1 | 2,021 | 2 | India | pass | compliant | not_applicable | 92.7 | 89.5 | 0 | 0 | none | 0.05 | under_5 | 0 |
49 | private_licensed | MAL_0091 | market_stall | peri_urban | mesoendemic | ML1 | artemether_lumefantrine_20_120 | ACT | tablet | first_line | 0.04 | 1 | 1 | 0 | 0 | 2,021 | 1 | unknown | fail | substandard | insufficient_artemisinin | 32.2 | 63.9 | 1 | 0 | moderate | 0.11 | 15_49 | 0 |
50 | private_licensed | MAL_0115 | private_pharmacy | peri_urban | holoendemic | ML1 | artesunate_amodiaquine | ACT | tablet | first_line | 0.05 | 1 | 0 | 0 | 0 | 2,023 | 4 | China | pass | compliant | not_applicable | 100 | 96.8 | 0 | 0 | none | 0.15 | 50_plus | 0 |
51 | private_licensed | MAL_0167 | private_pharmacy | peri_urban | holoendemic | ML1 | dihydroartemisinin_piperaquine | ACT | tablet | first_line | 0.06 | 1 | 1 | 0 | 0 | 2,023 | 4 | China | pass | compliant | not_applicable | 98.1 | 99.7 | 0 | 0 | high | 0.19 | 15_49 | 0 |
52 | private_licensed | MAL_0168 | itinerant_vendor | peri_urban | holoendemic | ML2 | artesunate_SP | ACT | tablet | IPTp | 0.04 | 0 | 0 | 0 | 0 | 2,021 | 1 | unknown | fail | substandard | insufficient_artemisinin | 79.6 | 76.2 | 1 | 0 | low | 0.11 | 15_49 | 0 |
53 | private_licensed | MAL_0031 | private_pharmacy | rural | hyperendemic | ML2 | artesunate_injection_60mg | injectable | injection | severe_malaria | 0.8 | 0 | 1 | 0 | 0 | 2,021 | 4 | local_SSA | pass | compliant | not_applicable | 100.6 | 91 | 0 | 0 | moderate | 2.28 | 15_49 | 0 |
54 | private_licensed | MAL_0072 | private_pharmacy | rural | hyperendemic | ML2 | artesunate_rectal_100mg | rectal | suppository | pre_referral | 0.5 | 0 | 1 | 0 | 0 | 2,023 | 4 | India | pass | compliant | not_applicable | 100.6 | 98 | 0 | 0 | none | 1.67 | 15_49 | 0 |
55 | private_licensed | MAL_0061 | private_pharmacy | urban | mesoendemic | ML3 | quinine_injection_300mg | injectable | injection | severe_malaria | 0.3 | 1 | 0 | 1 | 0 | 2,021 | 1 | India | pass | compliant | not_applicable | 99.8 | 100 | 0 | 0 | none | 0.58 | 50_plus | 0 |
56 | private_licensed | MAL_0149 | drug_shop | peri_urban | hypoendemic | ML2 | quinine_tablets_300mg | oral | tablet | second_line | 0.05 | 0 | 1 | 0 | 0 | 2,023 | 2 | India | pass | compliant | not_applicable | 100.7 | 93.2 | 0 | 0 | none | 0.17 | 15_49 | 0 |
57 | private_licensed | MAL_0162 | itinerant_vendor | rural | mesoendemic | ML4 | SP_sulfadoxine_pyrimethamine | SP | tablet | IPTp | 0.03 | 0 | 0 | 0 | 0 | 2,023 | 1 | India | fail | substandard | insufficient_artemisinin | 53.1 | 77.7 | 1 | 0 | high | 0.08 | under_5 | 0 |
58 | private_licensed | MAL_0091 | market_stall | urban | mesoendemic | ML1 | chloroquine_250mg | aminoquinoline | tablet | P_vivax | 0.01 | 1 | 0 | 1 | 0 | 2,022 | 4 | China | pass | compliant | not_applicable | 102.6 | 99.2 | 0 | 0 | none | 0.03 | under_5 | 0 |
59 | private_licensed | MAL_0045 | health_centre | rural | holoendemic | ML2 | primaquine_15mg | aminoquinoline | tablet | radical_cure | 0.08 | 0 | 1 | 0 | 0 | 2,024 | 3 | unknown | fail | falsified | counterfeit_packaging | 97.7 | 98.6 | 0 | 0 | moderate | 0.26 | 15_49 | 0 |
60 | private_licensed | MAL_0065 | market_stall | rural | hyperendemic | ML2 | oral_artemisinin_monotherapy | monotherapy_BANNED | tablet | banned_product | 0.02 | 0 | 0 | 0 | 1 | 2,024 | 4 | India | fail | falsified | no_artemisinin_detected | 0 | 85.3 | 1 | 0 | none | 0.05 | 15_49 | 1 |
61 | private_licensed | MAL_0068 | market_stall | urban | holoendemic | ML3 | artemether_lumefantrine_20_120 | ACT | tablet | first_line | 0.04 | 0 | 1 | 0 | 0 | 2,022 | 3 | local_SSA | fail | substandard | dissolution_failure | 88 | 105.8 | 0 | 0 | low | 0.11 | 15_49 | 0 |
62 | private_licensed | MAL_0152 | private_pharmacy | urban | mesoendemic | ML2 | artesunate_amodiaquine | ACT | tablet | first_line | 0.05 | 0 | 1 | 0 | 0 | 2,022 | 1 | unknown | pass | compliant | not_applicable | 92.9 | 90.9 | 0 | 0 | none | 0.14 | under_5 | 0 |
63 | private_licensed | MAL_0002 | drug_shop | rural | mesoendemic | ML1 | dihydroartemisinin_piperaquine | ACT | tablet | first_line | 0.06 | 1 | 0 | 0 | 0 | 2,022 | 3 | local_SSA | pass | compliant | not_applicable | 97.1 | 98.7 | 0 | 0 | none | 0.19 | under_5 | 0 |
64 | private_licensed | MAL_0128 | health_centre | urban | holoendemic | ML3 | artesunate_SP | ACT | tablet | IPTp | 0.04 | 0 | 1 | 0 | 0 | 2,023 | 3 | unknown | fail | falsified | wrong_API_entirely | 0 | 61.6 | 0 | 0 | low | 0.1 | under_5 | 0 |
65 | private_licensed | MAL_0104 | health_centre | rural | hyperendemic | ML2 | artesunate_injection_60mg | injectable | injection | severe_malaria | 0.8 | 1 | 1 | 0 | 0 | 2,021 | 1 | unknown | pass | compliant | not_applicable | 92.4 | 91.1 | 0 | 0 | none | 1.5 | under_5 | 0 |
66 | private_licensed | MAL_0192 | market_stall | peri_urban | hypoendemic | ML1 | artesunate_rectal_100mg | rectal | suppository | pre_referral | 0.5 | 0 | 1 | 0 | 0 | 2,024 | 4 | India | pass | compliant | not_applicable | 96 | 98.4 | 0 | 0 | none | 1.3 | under_5 | 0 |
67 | private_licensed | MAL_0044 | health_centre | rural | hyperendemic | ML2 | quinine_injection_300mg | injectable | injection | severe_malaria | 0.3 | 0 | 1 | 0 | 0 | 2,024 | 1 | India | pass | compliant | not_applicable | 101.4 | 105.6 | 0 | 0 | none | 0.95 | 15_49 | 0 |
68 | private_licensed | MAL_0194 | private_pharmacy | urban | holoendemic | ML3 | quinine_tablets_300mg | oral | tablet | second_line | 0.05 | 1 | 1 | 0 | 0 | 2,022 | 2 | Europe | pass | compliant | not_applicable | 100.6 | 101 | 0 | 0 | none | 0.19 | 5_14 | 0 |
69 | private_licensed | MAL_0184 | hospital_pharmacy | urban | mesoendemic | ML2 | SP_sulfadoxine_pyrimethamine | SP | tablet | IPTp | 0.03 | 1 | 0 | 0 | 0 | 2,023 | 3 | India | pass | compliant | not_applicable | 95.7 | 97.9 | 0 | 0 | none | 0.1 | under_5 | 0 |
70 | private_licensed | MAL_0087 | private_pharmacy | peri_urban | hypoendemic | ML4 | chloroquine_250mg | aminoquinoline | tablet | P_vivax | 0.01 | 0 | 1 | 0 | 0 | 2,022 | 4 | India | pass | compliant | not_applicable | 100.9 | 96.7 | 0 | 0 | high | 0.03 | 5_14 | 0 |
71 | private_licensed | MAL_0026 | health_centre | rural | mesoendemic | ML1 | primaquine_15mg | aminoquinoline | tablet | radical_cure | 0.08 | 1 | 0 | 1 | 0 | 2,023 | 2 | local_SSA | pass | compliant | not_applicable | 97.6 | 97.9 | 0 | 0 | none | 0.25 | 5_14 | 0 |
72 | private_licensed | MAL_0186 | health_centre | urban | hyperendemic | ML1 | oral_artemisinin_monotherapy | monotherapy_BANNED | tablet | banned_product | 0.02 | 0 | 1 | 0 | 1 | 2,024 | 1 | India | pass | compliant | not_applicable | 105.8 | 96.9 | 0 | 0 | none | 0.06 | under_5 | 0 |
73 | private_licensed | MAL_0074 | itinerant_vendor | urban | mesoendemic | ML2 | artemether_lumefantrine_20_120 | ACT | tablet | first_line | 0.04 | 0 | 1 | 0 | 0 | 2,021 | 4 | India | pass | compliant | not_applicable | 100.2 | 96.1 | 0 | 0 | moderate | 0.11 | 5_14 | 0 |
74 | private_licensed | MAL_0197 | itinerant_vendor | peri_urban | holoendemic | ML1 | artesunate_amodiaquine | ACT | tablet | first_line | 0.05 | 0 | 1 | 0 | 0 | 2,024 | 1 | unknown | pass | compliant | not_applicable | 95 | 97.9 | 0 | 0 | low | 0.16 | 5_14 | 0 |
75 | private_licensed | MAL_0043 | drug_shop | peri_urban | hyperendemic | ML2 | dihydroartemisinin_piperaquine | ACT | tablet | first_line | 0.06 | 1 | 1 | 1 | 0 | 2,024 | 4 | India | pass | compliant | not_applicable | 102.7 | 95.3 | 0 | 0 | none | 0.12 | 50_plus | 0 |
76 | private_licensed | MAL_0077 | itinerant_vendor | rural | holoendemic | ML1 | artesunate_SP | ACT | tablet | IPTp | 0.04 | 1 | 1 | 1 | 0 | 2,024 | 3 | China | pass | compliant | not_applicable | 100.3 | 95.9 | 0 | 0 | none | 0.09 | 50_plus | 0 |
77 | private_licensed | MAL_0023 | private_pharmacy | peri_urban | hypoendemic | ML2 | artesunate_injection_60mg | injectable | injection | severe_malaria | 0.8 | 0 | 1 | 1 | 0 | 2,023 | 1 | local_SSA | pass | compliant | not_applicable | 101.3 | 101.3 | 0 | 0 | none | 2.29 | under_5 | 0 |
78 | private_licensed | MAL_0118 | drug_shop | peri_urban | hyperendemic | ML4 | artesunate_rectal_100mg | rectal | suppository | pre_referral | 0.5 | 0 | 1 | 0 | 0 | 2,023 | 2 | India | pass | compliant | not_applicable | 99.7 | 109.6 | 0 | 0 | none | 1.42 | 5_14 | 1 |
79 | private_licensed | MAL_0160 | drug_shop | rural | hyperendemic | ML2 | quinine_injection_300mg | injectable | injection | severe_malaria | 0.3 | 0 | 0 | 0 | 0 | 2,023 | 4 | unknown | fail | substandard | disintegration_failure | 88.4 | 60.7 | 0 | 0 | low | 0.63 | under_5 | 0 |
80 | private_licensed | MAL_0075 | drug_shop | rural | holoendemic | ML1 | quinine_tablets_300mg | oral | tablet | second_line | 0.05 | 0 | 1 | 1 | 0 | 2,023 | 3 | unknown | pass | compliant | not_applicable | 100.9 | 94 | 0 | 0 | none | 0.12 | under_5 | 0 |
81 | private_licensed | MAL_0050 | health_centre | peri_urban | mesoendemic | ML1 | SP_sulfadoxine_pyrimethamine | SP | tablet | IPTp | 0.03 | 0 | 0 | 0 | 0 | 2,022 | 2 | Europe | fail | substandard | insufficient_artemisinin | 45.4 | 87.5 | 1 | 0 | moderate | 0.09 | under_5 | 0 |
82 | private_licensed | MAL_0140 | private_pharmacy | urban | mesoendemic | ML4 | chloroquine_250mg | aminoquinoline | tablet | P_vivax | 0.01 | 0 | 0 | 0 | 0 | 2,023 | 2 | unknown | pass | compliant | not_applicable | 97.9 | 103.4 | 0 | 0 | none | 0.03 | 5_14 | 0 |
83 | private_licensed | MAL_0098 | drug_shop | peri_urban | mesoendemic | ML1 | primaquine_15mg | aminoquinoline | tablet | radical_cure | 0.08 | 1 | 0 | 0 | 0 | 2,024 | 2 | unknown | pass | compliant | not_applicable | 99.6 | 97.5 | 0 | 0 | none | 0.23 | under_5 | 0 |
84 | private_licensed | MAL_0123 | private_pharmacy | urban | holoendemic | ML4 | oral_artemisinin_monotherapy | monotherapy_BANNED | tablet | banned_product | 0.02 | 0 | 0 | 0 | 1 | 2,021 | 2 | India | fail | falsified | expired_relabelled | 89.4 | 67.8 | 0 | 0 | low | 0.05 | 50_plus | 0 |
85 | private_licensed | MAL_0002 | private_pharmacy | urban | mesoendemic | ML3 | artemether_lumefantrine_20_120 | ACT | tablet | first_line | 0.04 | 1 | 0 | 0 | 1 | 2,023 | 2 | unknown | fail | falsified | wrong_API_entirely | 0 | 88.3 | 1 | 0 | high | 0.07 | under_5 | 0 |
86 | private_licensed | MAL_0113 | private_pharmacy | rural | hyperendemic | ML2 | artesunate_amodiaquine | ACT | tablet | first_line | 0.05 | 0 | 1 | 0 | 0 | 2,021 | 2 | local_SSA | pass | compliant | not_applicable | 101.8 | 104.3 | 0 | 0 | none | 0.14 | 5_14 | 0 |
87 | private_licensed | MAL_0039 | itinerant_vendor | rural | holoendemic | ML1 | dihydroartemisinin_piperaquine | ACT | tablet | first_line | 0.06 | 1 | 1 | 0 | 0 | 2,021 | 4 | Europe | pass | compliant | not_applicable | 97.1 | 100.9 | 0 | 0 | none | 0.2 | under_5 | 0 |
88 | private_licensed | MAL_0123 | market_stall | urban | holoendemic | ML3 | artesunate_SP | ACT | tablet | IPTp | 0.04 | 1 | 0 | 0 | 0 | 2,024 | 4 | unknown | pass | compliant | not_applicable | 101.4 | 98 | 0 | 0 | none | 0.09 | 15_49 | 0 |
89 | private_licensed | MAL_0124 | health_centre | urban | hyperendemic | ML2 | artesunate_injection_60mg | injectable | injection | severe_malaria | 0.8 | 0 | 1 | 0 | 0 | 2,021 | 2 | local_SSA | pass | compliant | not_applicable | 98.4 | 90.2 | 0 | 0 | low | 1.7 | 15_49 | 0 |
90 | private_licensed | MAL_0032 | private_pharmacy | rural | hyperendemic | ML4 | artesunate_rectal_100mg | rectal | suppository | pre_referral | 0.5 | 1 | 1 | 0 | 0 | 2,024 | 4 | India | pass | compliant | not_applicable | 99.3 | 100.3 | 0 | 0 | low | 1.1 | 15_49 | 0 |
91 | private_licensed | MAL_0187 | hospital_pharmacy | urban | mesoendemic | ML2 | quinine_injection_300mg | injectable | injection | severe_malaria | 0.3 | 0 | 1 | 0 | 0 | 2,020 | 4 | India | pass | compliant | not_applicable | 97.7 | 90.1 | 0 | 0 | moderate | 0.82 | under_5 | 0 |
92 | private_licensed | MAL_0082 | private_pharmacy | urban | holoendemic | ML4 | quinine_tablets_300mg | oral | tablet | second_line | 0.05 | 0 | 0 | 0 | 0 | 2,023 | 4 | India | pass | compliant | not_applicable | 101.6 | 97.2 | 0 | 0 | low | 0.09 | 15_49 | 0 |
93 | private_licensed | MAL_0053 | itinerant_vendor | rural | hyperendemic | ML1 | SP_sulfadoxine_pyrimethamine | SP | tablet | IPTp | 0.03 | 1 | 1 | 1 | 0 | 2,024 | 4 | India | pass | compliant | not_applicable | 96.6 | 95.4 | 0 | 0 | low | 0.09 | 50_plus | 0 |
94 | private_licensed | MAL_0088 | drug_shop | peri_urban | hyperendemic | ML2 | chloroquine_250mg | aminoquinoline | tablet | P_vivax | 0.01 | 1 | 0 | 0 | 0 | 2,021 | 3 | Europe | pass | compliant | not_applicable | 100.7 | 94.1 | 0 | 0 | none | 0.03 | under_5 | 0 |
95 | private_licensed | MAL_0091 | itinerant_vendor | urban | hyperendemic | ML1 | primaquine_15mg | aminoquinoline | tablet | radical_cure | 0.08 | 0 | 0 | 0 | 0 | 2,021 | 3 | local_SSA | fail | substandard | insufficient_artemisinin | 44 | 77.8 | 1 | 0 | moderate | 0.35 | under_5 | 0 |
96 | private_licensed | MAL_0093 | market_stall | peri_urban | hyperendemic | ML2 | oral_artemisinin_monotherapy | monotherapy_BANNED | tablet | banned_product | 0.02 | 0 | 1 | 0 | 1 | 2,023 | 3 | local_SSA | fail | substandard | insufficient_partner_drug | 78.2 | 90.3 | 0 | 0 | high | 0.04 | under_5 | 0 |
97 | private_licensed | MAL_0029 | hospital_pharmacy | peri_urban | mesoendemic | ML3 | artemether_lumefantrine_20_120 | ACT | tablet | first_line | 0.04 | 1 | 1 | 1 | 0 | 2,021 | 1 | China | pass | compliant | not_applicable | 98.2 | 96 | 0 | 0 | low | 0.08 | 50_plus | 0 |
98 | private_licensed | MAL_0032 | market_stall | rural | holoendemic | ML1 | artesunate_amodiaquine | ACT | tablet | first_line | 0.05 | 1 | 1 | 0 | 0 | 2,024 | 4 | China | pass | compliant | not_applicable | 93.7 | 101.8 | 0 | 0 | none | 0.17 | 15_49 | 0 |
99 | private_licensed | MAL_0187 | itinerant_vendor | rural | hypoendemic | ML3 | dihydroartemisinin_piperaquine | ACT | tablet | first_line | 0.06 | 1 | 1 | 0 | 0 | 2,023 | 2 | China | pass | compliant | not_applicable | 102.7 | 93.5 | 0 | 0 | none | 0.18 | under_5 | 0 |
100 | private_licensed | MAL_0197 | private_pharmacy | rural | hyperendemic | ML1 | artesunate_SP | ACT | tablet | IPTp | 0.04 | 1 | 1 | 0 | 0 | 2,020 | 2 | India | pass | compliant | not_applicable | 98.6 | 103.2 | 0 | 0 | none | 0.09 | 5_14 | 0 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.